title: Devices and drugs for stroke: why do regulations differ?
authors.affiliation: susanmayor@mac.com
authors.forename: Sue
authors.initials: S
authors.lastname: Mayor
mesh_terms: D002545:Brain Ischemia / Q000150:complications / Q000628:therapy; D002986:Clinical Trials as Topic; D017128:Embolectomy / Q000191:economics; D004864:Equipment and Supplies; D006801:Humans; D007880:Legislation, Drug / Q000639:trends*; D007883:Legislation, Medical / Q000639:trends*; D008279:Magnetic Resonance Imaging; D006278:Medicare / Q000331:legislation & jurisprudence; D010960:Plasminogen Activators / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy*; D017131:Thrombectomy / Q000191:economics / Q000295:instrumentation*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator